YDES vs BTBT vs NUVB vs IMVT vs AGEN

For growth investors, Nuvation Bio Inc.

(NUVB) is the stronger pick with 699. 0% revenue growth year-over-year, versus 10. 4% for Agenus Inc. (AGEN). Bit Digital, Inc. (BTBT) offers the better valuation at 9. 8x trailing P/E, making it the more compelling value choice. Analysts rate Bit Digital, Inc. (BTBT) a "Buy" — based on 2 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Immunovant, Inc.

(IMVT) delivered a total return of +83. 3%, compared to -94. 3% for Agenus Inc. (AGEN). Over 10 years, the gap is even starker: IMVT returned +187. 9% versus AGEN's -94. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), YD Bio Limited Ordinary Shares (YDES) is the lower-risk stock at 0.

80β versus Bit Digital, Inc. 's 3. 41β — meaning BTBT is approximately 328% more volatile than YDES relative to the S&P 500. On balance sheet safety, Immunovant, Inc. (IMVT) carries a lower debt/equity ratio of 0% versus 3% for Nuvation Bio Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Nuvation Bio Inc.

(NUVB) is pulling ahead at 699. 0% versus 10. 4% for Agenus Inc. (AGEN). On earnings-per-share growth, the picture is similar: Bit Digital, Inc. grew EPS 225. 0% year-over-year, compared to -45. 2% for Immunovant, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Bit Digital, Inc.

(BTBT) is the more profitable company, earning 17. 3% net margin versus -325. 3% for Nuvation Bio Inc. — meaning it keeps 17. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: BTBT leads at 16. 8% versus -338. 7% for NUVB. At the gross margin level — before operating expenses — AGEN leads at 90. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for NUVB: 156.

2% to $12. 40.

In this comparison, BTBT (0.

3% yield) pays a dividend. YDES, NUVB, IMVT, AGEN do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, YD Bio Limited Ordinary Shares (YDES) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

80)). Agenus Inc. (AGEN) carries a higher beta of 2. 58 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (YDES: -56. 9%, AGEN: -94. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (YDES (Healthcare) and BTBT (Financial Services) and NUVB (Healthcare) and IMVT (Healthcare) and AGEN (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: YDES is a small-cap high-growth stock; BTBT is a small-cap high-growth stock; NUVB is a small-cap high-growth stock; IMVT is a small-cap quality compounder stock; AGEN is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.